Eli Lilly has announced promising results from its first Phase 3 clinical trial for orforglipron, a once-daily oral GLP-1 receptor agonist. The trial results show significant reductions in both blood sugar (A1C levels) and body weight among adults with type 2 diabetes, setting the stage for a potential new alternative to injectable therapies.
Strong Efficacy in Blood Sugar and Weight Reduction
The trial, which included 559 participants with type 2 diabetes who had not used anti-diabetic medications or insulin for at least 90 days prior, evaluated orforglipron as a standalone treatment. At 40 weeks, participants saw average A1C reductions of:
-
1.3% with the low dose
-
1.6% with the middle dose
-
1.5% with the high dose
-
This compares to a 0.1% reduction in the placebo group.
Importantly, over 65% of participants in the high-dose group achieved A1C levels of 6.5% or below — the American Diabetes Association’s threshold for diagnosing diabetes.
When it came to weight loss, the high-dose group lost an average of 7.9% of body weight, equivalent to about 16 pounds (7.3 kg), compared to just 2.9 pounds (1.3 kg) in the placebo group. Notably, Lilly reported that patients had not yet reached a plateau in weight loss by the end of the trial, suggesting continued use may lead to further reductions.
Tolerability and Safety
As with other GLP-1 therapies, the most common side effects were gastrointestinal, including nausea, diarrhea, constipation, indigestion, and vomiting. These were generally mild to moderate in severity. The highest discontinuation rate was 8%, occurring in the highest dose group. Crucially, no liver safety signals were reported — a significant detail after Pfizer recently halted development of its oral GLP-1 candidate, danuglipron, due to liver toxicity concerns.
A Game-Changer in Metabolic Medicine?
Currently available GLP-1 medications, such as Ozempic and Wegovy, are injectable peptides that require refrigeration and have specific dietary restrictions. Orforglipron represents a different class: a small molecule GLP-1 drug that:
-
Does not require refrigeration
-
Has no food or beverage restrictions
-
Can be manufactured and scaled more efficiently
These advantages could make orforglipron particularly impactful in low- and middle-income countries, where access to injectable medications can be limited due to cost or storage requirements.
According to Lilly CEO David Ricks, “As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world.”
Regulatory Outlook and Competitive Landscape
Lilly plans to submit orforglipron for weight management approval globally by the end of 2025, followed by U.S. FDA submission for type 2 diabetes in 2026. The drug is part of a broader development program that includes seven Phase 3 studies for both obesity and diabetes.
While comparisons between clinical trials must be made cautiously, analysts note that orforglipron’s outcomes stack up well against semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Rybelsus. However, differences in trial design and patient backgrounds, such as baseline A1C and concurrent use of metformin, make direct comparisons challenging.
Some analysts, including William Blair’s Andy Hsieh, believe injectable GLP-1s will remain dominant in high-income countries due to their higher potency. Still, oral drugs like orforglipron could become essential tools in regions with less healthcare infrastructure.
Looking Ahead
Lilly will present complete trial data during the American Diabetes Association’s annual scientific sessions in June. Additional trial results for orforglipron are expected later this year.
As the race to develop effective, accessible GLP-1 therapies intensifies, Lilly’s oral candidate may soon revolutionize the treatment of type 2 diabetes and obesity, potentially reaching millions worldwide with a more convenient and scalable solution.
📌 Stay tuned for more updates from upcoming clinical trials and FDA regulatory milestones.
📞 Want to learn more about cutting-edge metabolic therapies? Book a consultation with 1st Optimal to explore your personalized options.
Guided Medical Oversight at 1st Optimal
At 1st Optimal, we understand that health optimization is a journey. Our team of experienced medical providers can help you understand your hormone levels and create a personalized plan tailored to your needs. Schedule a free consultation with the 1st Optimal Care Team and take the first step toward achieving better hormonal balance, improved sleep, weight loss, and improved body composition.
If you’re ready to take the next step toward optimal health, we’re here to help. Contact us to schedule an appointment or learn more about our services:
- Email: membersupport@1stoptimal.com
- Phone: (816) 744-6814
- Online Booking: 1st Optimal Booking Link
